Item 8.01. Other Events
On September 11, 2009, Theravance, Inc. issued a press release announcing that
the U.S. Food and Drug Administration (FDA) approved VIBATIV(TM) (telavancin)
for the treatment of adult patients with complicated skin and skin structure
infections caused by susceptible Gram-positive bacteria, including
Staphylococcus aureus, both methicillin-resistant (MRSA) and
methicillin-susceptible (MSSA) strains. A copy of the press release is filed as
Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release of Theravance, Inc. dated September 11,
2009
Add
THRX to Portfolio
Set Alert
Email to a
Friend